Skip to content
2000
image of COL4A1 Promotes Gastric Cancer Progression by Regulating Tumor Invasion, Tumor Microenvironment and Drug Sensitivity
file format pdf download PDF

Abstract

Background

Collagen type IV alpha 1 chain (COL4A1), which has been proven to be a potential biomarker in Gastric Cancer (GC), but its role in tumors and the tumor microenvironment (TME) needs further explanation.

Methods

We analysed the relationship between COL4A1 and clinical characteristics based on The Cancer Genome Atlas (TCGA) database and verified by tissue microarrays as well as GC cell lines using immunohistochemistry, Q-PCR, Western blot, cell proliferation assays, colony formation assays, cell invasion and migration assays. The immune infiltration and drug sensitivity information between high and low COL4A1 expression were analysed by R package and pRRophetic package. Finally, we established a nomogram based on COL4A1 expression using the bootstrap method.

Results

COL4A1 was overexpressed in gastric carcinoma compared with normal gastric tissue, indicating a poor prognosis of GC patients in the TCGA database which were also validated by GC tissue microarrays. GO, KEGG and hallmark enrichment analyses indicated that COL4A1 was mainly associated with the extracellular matrix than malignant proliferation. By siRNA transfection, we found that COL4A1 knockdown inhibited cell colony formation, invasion and migration but did not affect cell proliferation, similar to previous results. Immune infiltration and drug sensitivity analysis showed that COL4A1 was negatively correlated with antitumor immunity and positively correlated with multidrug resistance. By developing a nomogram model based on 8 risk factors, including COL4A1, patients with better clinical outcomes could be accurately distinguished.

Conclusion

COL4A1 is identified as a prognostic marker and potential therapeutic target in gastric cancer. Its overexpression correlates with poor prognosis, tumor invasion, and immunosuppression. A nomogram based on COL4A1 can predict patient outcomes. Future research should validate these findings and explore targeted therapies.

© 2025 The Author(s). Published by Bentham Science Publisher.
This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode.
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673351943250314074632
2025-04-07
2025-09-09

  • From This Site

    /content/journals/cmc/10.2174/0109298673351943250314074632
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cmc/10.2174/0109298673351943250314074632/BMS-CMC-2024-614.html?itemId=/content/journals/cmc/10.2174/0109298673351943250314074632&mimeType=html&fmt=ahah

References

  1. Ford H.E.R. Marshall A. Bridgewater J.A. Janowitz T. Coxon F.Y. Wadsley J. Mansoor W. Fyfe D. Madhusudan S. Middleton G.W. Swinson D. Falk S. Chau I. Cunningham D. Kareclas P. Cook N. Blazeby J.M. Dunn J.A. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): An open-label, phase 3 randomised controlled trial. Lancet Oncol. 2014 15 1 78 86 10.1016/S1470‑2045(13)70549‑7 24332238
    [Google Scholar]
  2. Bang Y.J. Van Cutsem E. Feyereislova A. Chung H.C. Shen L. Sawaki A. Lordick F. Ohtsu A. Omuro Y. Satoh T. Aprile G. Kulikov E. Hill J. Lehle M. Rüschoff J. Kang Y.K. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 2010 376 9742 687 697 10.1016/S0140‑6736(10)61121‑X 20728210
    [Google Scholar]
  3. Fuchs C.S. Doi T. Jang R.W. Muro K. Satoh T. Machado M. Sun W. Jalal S.I. Shah M.A. Metges J.P. Garrido M. Golan T. Mandala M. Wainberg Z.A. Catenacci D.V. Ohtsu A. Shitara K. Geva R. Bleeker J. Ko A.H. Ku G. Philip P. Enzinger P.C. Bang Y.J. Levitan D. Wang J. Rosales M. Dalal R.P. Yoon H.H. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer. JAMA Oncol. 2018 4 5 e180013 10.1001/jamaoncol.2018.0013 29543932
    [Google Scholar]
  4. Kang Y.K. Boku N. Satoh T. Ryu M.H. Chao Y. Kato K. Chung H.C. Chen J.S. Muro K. Kang W.K. Yeh K.H. Yoshikawa T. Oh S.C. Bai L.Y. Tamura T. Lee K.W. Hamamoto Y. Kim J.G. Chin K. Oh D.Y. Minashi K. Cho J.Y. Tsuda M. Chen L.T. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017 390 10111 2461 2471 10.1016/S0140‑6736(17)31827‑5 28993052
    [Google Scholar]
  5. Fuchs C.S. Tomasek J. Yong C.J. Dumitru F. Passalacqua R. Goswami C. Safran H. dos Santos L.V. Aprile G. Ferry D.R. Melichar B. Tehfe M. Topuzov E. Zalcberg J.R. Chau I. Campbell W. Sivanandan C. Pikiel J. Koshiji M. Hsu Y. Liepa A.M. Gao L. Schwartz J.D. Tabernero J. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014 383 9911 31 39 10.1016/S0140‑6736(13)61719‑5 24094768
    [Google Scholar]
  6. Kawazoe A. Fukuoka S. Nakamura Y. Kuboki Y. Wakabayashi M. Nomura S. Mikamoto Y. Shima H. Fujishiro N. Higuchi T. Sato A. Kuwata T. Shitara K. Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): An open-label, single-arm, phase 2 trial. Lancet Oncol. 2020 21 8 1057 1065 10.1016/S1470‑2045(20)30271‑0 32589866
    [Google Scholar]
  7. Cancer Genome Atlas Research Network Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014 513 7517 202 209 10.1038/nature13480 25079317
    [Google Scholar]
  8. Nakamura Y. Kawazoe A. Lordick F. Janjigian Y.Y. Shitara K. Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: An emerging paradigm. Nat. Rev. Clin. Oncol. 2021 18 8 473 487 10.1038/s41571‑021‑00492‑2 33790428
    [Google Scholar]
  9. Rha S.Y. Oh D.Y. Yañez P. Bai Y. Ryu M.H. Lee J. Rivera F. Alves G.V. Garrido M. Shiu K.K. Fernández M.G. Li J. Lowery M.A. Çil T. Cruz F.M. Qin S. Luo S. Pan H. Wainberg Z.A. Yin L. Bordia S. Bhagia P. Wyrwicz L.S. Mendez G. O’Connor J.M. Yanzi Castilla A. Cundom J. Kaen D. Wong R. Ng W. Aghmesheh M. Peressoni M. Andrade C. Franke F. Alves G. Cruz F.J. Vianna K. Monteiro M.M. Raphael M. Berry S. Jang R. Tan A. Asselah J. Yanez Weber P. Mahave M. Sanchez C. Salman P. Bai Y. Li J. Zhang X. Liu T. Lin X. Qin S. Yang J. Luo S. Li W. Ying J. Chen X. Zeng S. Qu Y. Yang L. Zhao L. Chen P. Pan H. Li E. Ye F. Lu J. Liang X. Zhao Q. Yin X. Li J. Ling Y. Lv G. Li S. Guerrero A. Rubiano J. Gonzalez Fernandez M. Manneh Kopp R. Guzman Ramirez A. Corrales L. Gonzalez Herrera I. Melichar B. Buchler T. Svoboda T. Obermannova R. Vrana D. Cvek J. Pfeiffer P. Baeksgaard L. Yilmaz M. Boige V. Lopez-Trabada D. Borg C. Pannier D. Hiret S. Di Fiore F. Metges J-P. Arnold D. Martens U. Lordick F. Stein A. Castro H. Lopez K. Ramirez J. Aguilar M. Chivalan M. Chan W. Cheng A. Yeo W. Arkosy P. Csoszi T. Hitre E. Horvath Z. Lowery M. McDermott R. Morris P. Hubert A. Brenner B. Ben-Aharon I. Shacham-Shmueli E. Man S. Pelles Avraham S. Brenner R. Mishaeli M. Di Bartolomeo M. Fazio N. Lonardi S. Garufi C. Satoh T. Hara H. Iwagami S. Yasui H. Tsuda M. Shimoyama T. Shoji H. Sugimoto N. Shibata N. Yamaguchi K. Amagai K. Choda Y. Esaki T. Yabusaki H. Oshima T. Tsuji A. Kawakami H. Kawazoe A. Ishido K. Kadowaki S. Martinez Rodriguez J. Herrera Martinez M. Huitzil Melendez F. Ramirez Godinez F. Balancan P. Damianovich D. Castro Oliden V. Grados J. Torres C. Wyrwicz L. Wysocki P. Hajac L. Zolnierek J. Karaszewska B. Rha S.Y. Lee J. Ryu M-H. Oh D-Y. Orlova R. Tjulandin S. Fadeeva N. Makarycheva Y. Nosov D. Smagina M. Chan S. Jacobs C. Kraus P. Landers G. Robertson B. Ruff P. Schoeman E. Maurel J-M. Diez Garcia M. Jimenez Fonseca P. Gallego Plazas J. Rivera Herrero F. Miranda Poma J. Layos Romero L. Fritsch R. Bastian S. Winterhalder R. Dosso S.D. Kossler T. Yeh K-H. Yen C-J. Chen Y-Y. Lin J. Bilici M. Ozguroglu M. Cil T. Oksuzoglu B. Harputluoglu H. Karaoglu A. Hacibekiroglu I. Erdogan B. Yalcin S. Adamchuk H. Bondarenko I. Kolesnik O. Ostapenko Y. Kryzhanivska A. Leshchenko L. Ilin I. Shparyk Y. Trukhin D. Voitko N. Roy R. Young A-M. Medley L. Shiu K-K. Celano P. Overton L. Raj M. Dunne R. Wainberg Z. Dayyani F. Larson T. Kochenderfer M. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): A multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023 24 11 1181 1195 10.1016/S1470‑2045(23)00515‑6 37875143
    [Google Scholar]
  10. Janjigian Y.Y. Shitara K. Moehler M. Garrido M. Salman P. Shen L. Wyrwicz L. Yamaguchi K. Skoczylas T. Campos Bragagnoli A. Liu T. Schenker M. Yanez P. Tehfe M. Kowalyszyn R. Karamouzis M.V. Bruges R. Zander T. Pazo-Cid R. Hitre E. Feeney K. Cleary J.M. Poulart V. Cullen D. Lei M. Xiao H. Kondo K. Li M. Ajani J.A. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial. Lancet 2021 398 10294 27 40 10.1016/S0140‑6736(21)00797‑2 34102137
    [Google Scholar]
  11. Rizzo A. Santoni M. Mollica V. Logullo F. Rosellini M. Marchetti A. Faloppi L. Battelli N. Massari F. Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: The MOUSEION-02 study. Expert Opin. Drug Metab. Toxicol. 2021 17 12 1455 1466 10.1080/17425255.2021.2029405 35029519
    [Google Scholar]
  12. Guven D.C. Erul E. Kaygusuz Y. Akagunduz B. Kilickap S. De Luca R. Rizzo A. Immune checkpoint inhibitor-related hearing loss: A systematic review and analysis of individual patient data. Support. Care Cancer 2023 31 11 624 10.1007/s00520‑023‑08083‑w 37819422
    [Google Scholar]
  13. Kennedy L.B. Salama A.K.S. A review of cancer immunotherapy toxicity. CA Cancer J. Clin. 2020 70 2 86 104 10.3322/caac.21596 31944278
    [Google Scholar]
  14. Patel T.H. Cecchini M. Targeted therapies in advanced gastric cancer. Curr. Treat. Options Oncol. 2020 21 9 70 10.1007/s11864‑020‑00774‑4 32725377
    [Google Scholar]
  15. Sahin T.K. Rizzo A. Aksoy S. Guven D.C. Prognostic significance of the royal marsden hospital (RMH) score in patients with cancer: A systematic review and meta-analysis. Cancers (Basel) 2024 16 10 1835 10.3390/cancers16101835 38791914
    [Google Scholar]
  16. Van Cutsem E. Bang Y.J. Mansoor W. Petty R.D. Chao Y. Cunningham D. Ferry D.R. Smith N.R. Frewer P. Ratnayake J. Stockman P.K. Kilgour E. Landers D. A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification. Ann. Oncol. 2017 28 6 1316 1324 10.1093/annonc/mdx107 29177434
    [Google Scholar]
  17. Catenacci D.V.T. Tebbutt N.C. Davidenko I. Murad A.M. Al-Batran S.E. Ilson D.H. Tjulandin S. Gotovkin E. Karaszewska B. Bondarenko I. Tejani M.A. Udrea A.A. Tehfe M. De Vita F. Turkington C. Tang R. Ang A. Zhang Y. Hoang T. Sidhu R. Cunningham D. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 18 11 1467 1482 10.1016/S1470‑2045(17)30566‑1 28958504
    [Google Scholar]
  18. Bang Y.J. Xu R.H. Chin K. Lee K.W. Park S.H. Rha S.Y. Shen L. Qin S. Xu N. Im S.A. Locker G. Rowe P. Shi X. Hodgson D. Liu Y.Z. Boku N. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first- line therapy (GOLD): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 18 12 1637 1651 10.1016/S1470‑2045(17)30682‑4 29103871
    [Google Scholar]
  19. Ricci A.D. Rizzo A. Brandi G. DNA damage response alterations in gastric cancer: Knocking down a new wall. Future Oncol. 2021 17 8 865 868 10.2217/fon‑2020‑0989 33508962
    [Google Scholar]
  20. Rihawi K. Ricci A.D. Rizzo A. Brocchi S. Marasco G. Pastore L.V. Llimpe F.L.R. Golfieri R. Renzulli M. Tumor-associated macrophages and inflammatory microenvironment in gastric cancer: Novel translational implications. Int. J. Mol. Sci. 2021 22 8 3805 10.3390/ijms22083805 33916915
    [Google Scholar]
  21. Türeci O. Sahin U. Schulze-Bergkamen H. Zvirbule Z. Lordick F. Koeberle D. Thuss-Patience P. Ettrich T. Arnold D. Bassermann F. Al-Batran S.E. Wiechen K. Dhaene K. Maurus D. Gold M. Huber C. Krivoshik A. Arozullah A. Park J.W. Schuler M. A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: The MONO study. Ann. Oncol. 2019 30 9 1487 1495 10.1093/annonc/mdz199 31240302
    [Google Scholar]
  22. Cao W. Xing H. Li Y. Tian W. Song Y. Jiang Z. Yu J. Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy. Biomark. Res. 2022 10 1 38 10.1186/s40364‑022‑00385‑1 35642043
    [Google Scholar]
  23. Qi C. Gong J. Li J. Liu D. Qin Y. Ge S. Zhang M. Peng Z. Zhou J. Cao Y. Zhang X. Lu Z. Lu M. Yuan J. Wang Z. Wang Y. Peng X. Gao H. Liu Z. Wang H. Yuan D. Xiao J. Ma H. Wang W. Li Z. Shen L. Claudin18.2-specific CAR T cells in gastrointestinal cancers: Phase 1 trial interim results. Nat. Med. 2022 28 6 1189 1198 10.1038/s41591‑022‑01800‑8 35534566
    [Google Scholar]
  24. Li D.F. Wang N.N. Chang X. Wang S.L. Wang L.S. Yao J. Li Z.S. Bai Y. Bioinformatics analysis suggests that COL4A1 may play an important role in gastric carcinoma recurrence. J. Dig. Dis. 2019 20 8 391 400 10.1111/1751‑2980.12758 31069993
    [Google Scholar]
  25. Cheng J. Zhuo H. Wang L. Zheng W. Chen X. Hou J. Zhao J. Cai J. Identification of the combinatorial effect of miRNA family regulatory network in different growth patterns of GC. Mol. Ther. Oncolytics 2020 17 531 546 10.1016/j.omto.2020.03.012 32637572
    [Google Scholar]
  26. Cui X. Shan T. Qiao L. Collagen type IV alpha 1 (COL4A1) silence hampers the invasion, migration and epithelial–mesenchymal transition (EMT) of gastric cancer cells through blocking Hedgehog signaling pathway. Bioengineered 2022 13 4 8972 8981 10.1080/21655979.2022.2053799 35297303
    [Google Scholar]
  27. Schmittgen T.D. Livak K.J. Analyzing real-time PCR data by the comparative CT method. Nat. Protoc. 2008 3 6 1101 1108 10.1038/nprot.2008.73 18546601
    [Google Scholar]
  28. Győrffy B. Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer. Comput. Struct. Biotechnol. J. 2021 19 4101 4109 10.1016/j.csbj.2021.07.014 34527184
    [Google Scholar]
  29. Ritchie M.E. Phipson B. Wu D. Hu Y. Law C.W. Shi W. Smyth G.K. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015 43 7 e47 10.1093/nar/gkv007 25605792
    [Google Scholar]
  30. Newman A.M. Liu C.L. Green M.R. Gentles A.J. Feng W. Xu Y. Hoang C.D. Diehn M. Alizadeh A.A. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 2015 12 5 453 457 10.1038/nmeth.3337 25822800
    [Google Scholar]
  31. Yoshihara K. Shahmoradgoli M. Martínez E. Vegesna R. Kim H. Torres-Garcia W. Treviño V. Shen H. Laird P.W. Levine D.A. Carter S.L. Getz G. Stemke-Hale K. Mills G.B. Verhaak R.G.W. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 2013 4 1 2612 10.1038/ncomms3612 24113773
    [Google Scholar]
  32. Geeleher P. Cox N. Huang R.S. pRRophetic: An R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS One 2014 9 9 e107468 10.1371/journal.pone.0107468 25229481
    [Google Scholar]
  33. Liu C. Somasundaram A. Manne S. Gocher A.M. Szymczak-Workman A.L. Vignali K.M. Scott E.N. Normolle D.P. John Wherry E. Lipson E.J. Ferris R.L. Bruno T.C. Workman C.J. Vignali D.A.A. Neuropilin-1 is a T cell memory checkpoint limiting long-term antitumor immunity. Nat. Immunol. 2020 21 9 1010 1021 10.1038/s41590‑020‑0733‑2 32661362
    [Google Scholar]
  34. Morgan H.J. Rees E. Lanfredini S. Powell K.A. Gore J. Gibbs A. Lovatt C. Davies G.E. Olivero C. Shorning B.Y. Tornillo G. Tonks A. Darley R. Wang E.C.Y. Patel G.K. CD200 ectodomain shedding into the tumor microenvironment leads to NK cell dysfunction and apoptosis. J. Clin. Invest. 2022 132 21 e150750 10.1172/JCI150750 36074574
    [Google Scholar]
  35. Wang C. Li Y. Jia L. Kim J.K. Li J. Deng P. Zhang W. Krebsbach P.H. Wang C.-Y. CD276 expression enables squamous cell carcinoma stem cells to evade immune surveillance. Cell Stem Cell. 2021 28 9 1597 1613.e7 10.1016/j.stem.2021.04.011 33945793
    [Google Scholar]
  36. Janjigian Y.Y. Bendell J. Calvo E. Kim J.W. Ascierto P.A. Sharma P. Ott P.A. Peltola K. Jaeger D. Evans J. de Braud F. Chau I. Harbison C.T. Dorange C. Tschaika M. Le D.T. Checkmate-032 study: Efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. J. Clin. Oncol. 2018 36 28 2836 2844 10.1200/JCO.2017.76.6212 30110194
    [Google Scholar]
  37. Shitara K. Lordick F. Bang Y.J. Enzinger P. Ilson D. Shah M.A. Van Cutsem E. Xu R.H. Aprile G. Xu J. Chao J. Pazo-Cid R. Kang Y.K. Yang J. Moran D. Bhattacharya P. Arozullah A. Park J.W. Oh M. Ajani J.A. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): A multicentre, randomised, double-blind, phase 3 trial. Lancet 2023 401 10389 1655 1668 10.1016/S0140‑6736(23)00620‑7 37068504
    [Google Scholar]
  38. Shah M.A. Shitara K. Ajani J.A. Bang Y.J. Enzinger P. Ilson D. Lordick F. Van Cutsem E. Gallego Plazas J. Huang J. Shen L. Oh S.C. Sunpaweravong P. Soo Hoo H.F. Turk H.M. Oh M. Park J.W. Moran D. Bhattacharya P. Arozullah A. Xu R.H. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: The randomized, phase 3 GLOW trial. Nat. Med. 2023 29 8 2133 2141 10.1038/s41591‑023‑02465‑7 37524953
    [Google Scholar]
  39. Yuan Z. Li Y. Zhang S. Wang X. Dou H. Yu X. Zhang Z. Yang S. Xiao M. Extracellular matrix remodeling in tumor progression and immune escape: From mechanisms to treatments. Mol. Cancer 2023 22 1 48 10.1186/s12943‑023‑01744‑8 36906534
    [Google Scholar]
/content/journals/cmc/10.2174/0109298673351943250314074632
Loading
COL4A1 Promotes Gastric Cancer Progression by Regulating Tumor Invasion, Tumor Microenvironment and Drug Sensitivity
Bentham Science Publishers ; https://doi.org/10.2174/0109298673351943250314074632
/content/journals/cmc/10.2174/0109298673351943250314074632
/content/journals/cmc/10.2174/0109298673351943250314074632
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher's website along with the published article.

file format download Download

  • Article Type:     Research Article
Keywords: western blot ; Collagen IV ; COL4A1 ; gastric cancer ; immune infiltration ; nomogram

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test